NCT05220098 is a Phase 1, PHASE2 clinical trial of TAK-280 in Unresectable Locally Advanced or Metastatic Cancer, sponsored by Takeda.

Who is sponsoring NCT05220098?

NCT05220098 is sponsored by Takeda.

What drugs are being tested in NCT05220098?

Interventions in NCT05220098: TAK-280.

What condition does NCT05220098 study?

NCT05220098 studies Unresectable Locally Advanced or Metastatic Cancer.

Is NCT05220098 still recruiting?

NCT05220098 is currently terminated. Last updated 29 August 2025.

Last reviewed 2025-08-29 · How we verify

NCT05220098

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-Human Study of TAK-280 in Participants With Solid Tumors

Terminated Phase 1, PHASE2 Last updated 29 August 2025

What this trial tests

Phase 1, PHASE2 trial testing TAK-280 in Unresectable Locally Advanced or Metastatic Cancer in 69 participants. Terminated before completion.

Timeline

22 April 2022

Primary endpoint
28 July 2025

28 July 2025

Quick facts

Lead sponsor	Takeda
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	69
Start date	22 April 2022
Primary completion	28 July 2025
Estimated completion	28 July 2025
Sites	23 locations across Canada, United States, Australia, Spain

Drugs / interventions tested

TAK-280 — full drug profile →

Conditions studied

Unresectable Locally Advanced or Metastatic Cancer — all drugs for Unresectable Locally Advanced or Metastatic Cancer →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Unresectable Locally Advanced or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Exploiting protease activation for therapy.
Bleuez C, Koch WF, Urbach C, Hollfelder F, et al · · 2022 · cited 27× · PMID 35314338 · DOI 10.1016/j.drudis.2022.03.011
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions.
Ai Z, Wang B, Song Y, Cheng P, et al · · 2025 · cited 15× · PMID 39911391 · DOI 10.3389/fimmu.2025.1523693
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy.
McCue AC, Demarest SJ, Froning KJ, Hickey MJ, et al · · 2024 · cited 9× · PMID 38962811 · DOI 10.1080/19420862.2024.2373325
Research progress of B7-H3 in malignant tumors.
Zhao S, Zhang H, Shang G. · · 2025 · cited 6× · PMID 40519928 · DOI 10.3389/fimmu.2025.1586759
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer.
Wen J, Cui W, Yin X, Chen Y, et al · · 2025 · cited 5× · PMID 40192238 · DOI 10.20892/j.issn.2095-3941.2024.0470
Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.
Abodunrin F, Olson DJ, Emehinola O, Bestvina CM. · · 2025 · cited 5× · PMID 40012708 · DOI 10.1177/17588359251320280
Current landscape of T-cell engagers in early-phase clinical development in solid cancers.
Spinazzola A, Iannantuono GM, Gulley JL, Giudice E, et al · · 2025 · cited 3× · PMID 41122165 · DOI 10.3389/fimmu.2025.1665838
Reprogramming the Tumor Immune Microenvironment with ICAM-1-Targeted Antibody‒Drug Conjugates and B7-H3-CD3 Bispecific Antibodies.
Zhou S, Hong M, Zhao D, Li W, et al · · 2025 · cited 3× · PMID 39996528 · DOI 10.1002/advs.202415577

Verify or expand the search:

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05220098 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 29 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05220098.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing